Activation barriers to structural transition determine deposition rates of Alzheimer's disease a beta amyloid.

Brain amyloid composed of the approximately 40-amino-acid human beta-amyloid peptide A beta is integral to Alzheimer's disease pathology. To probe the importance of a conformational transition in Abeta during amyloid growth, we synthesized and examined the solution conformation and amyloid deposition activity of A beta congeners designed to have similar solution structures but to vary substantially in their barriers to conformational transition. Although all these peptides adopt similar solution conformations, a covalently restricted Abeta congener designed to have a very high barrier to conformational rearrangement was inactive, while a peptide designed to have a reduced barrier to conformational transition displayed an enhanced deposition rate relative to wild-type A beta. The hyperactive peptide, which is linked to a heritable A beta amyloidosis characterized by massive amyloid deposition at an early age, displayed a reduced activation barrier to deposition consistent with a larger difference in activation entropy than in activation enthalpy relative to wild-type A beta. These results suggest that in Alzheimer's disease, as in the prion diseases, a conformational transition in the depositing peptide is essential for the conversion of soluble monomer to insoluble amyloid, and alterations in the activation barrier to this transition affect amyloidogenicity and directly contribute to human disease.

[1]  D. Selkoe,et al.  Alzheimer's Disease: A Central Role for Amyloid , 1994, Journal of neuropathology and experimental neurology.

[2]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology Confirmation of the Clinical Diagnosis of Alzheimer's Disease , 1995, Neurology.

[3]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[4]  Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[6]  H. Vinters,et al.  Stereochemical specificity of Alzheimer's disease β-peptide assembly , 1999 .

[7]  George B. Benedek,et al.  Temperature dependence of amyloid β-protein fibrillization , 1998 .

[8]  J. Lee,et al.  Selectively 2H‐labeledGlu/Asp: application to pKa measurements in Aβ amyloid peptides , 2000 .

[9]  N Casey,et al.  Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster. , 1998, Folding & design.

[10]  R. Roos,et al.  Hereditary Cerebral Hemorrhage with Amyloidosis‐Dutch Type (HCHWA‐D): I ‐ A Review of Clinical, Radiologic and Genetic Aspects , 1996, Brain pathology.

[11]  J R Ghilardi,et al.  In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. , 1996, Biochemistry.

[12]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[13]  B D Sykes,et al.  Chemical shifts as a tool for structure determination. , 1994, Methods in enzymology.

[14]  P E Fraser,et al.  Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: analysis by x-ray diffraction. , 1993, Biophysical journal.

[15]  R. Wetzel.  For Protein Misassembly, It's the “I” Decade , 1996, Cell.

[16]  H. Vinters,et al.  Point Substitution in the Central Hydrophobic Cluster of a Human β-Amyloid Congener Disrupts Peptide Folding and Abolishes Plaque Competence† , 1996 .

[17]  H. Vinters,et al.  Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. , 1999, Biochemistry.

[18]  P. Mantyh,et al.  Brain Amyloid — A Physicochemical Perspective , 1996, Brain pathology.

[19]  H. Naiki,et al.  First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[20]  F. Richards,et al.  The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. , 1992, Biochemistry.

[21]  M. Schiffer,et al.  Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains , 2008, Protein science : a publication of the Protein Society.

[22]  P. Lansbury,et al.  Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. , 1990, Biochemistry.

[23]  D. Kirschner,et al.  Refined fibril structures: the hydrophobic core in Alzheimer's amyloid beta-protein and prion as revealed by X-ray diffraction. , 1996, Ciba Foundation symposium.

[24]  H. Vinters,et al.  Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy , 1990, Annals of neurology.

[25]  P. Mantyh,et al.  Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. , 1999, Methods in enzymology.

[26]  J R Ghilardi,et al.  Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.

[27]  D. Selkoe,et al.  X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Z. Khachaturian.  Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[29]  G. Glenner,et al.  Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. , 1984, Biochemical and biophysical research communications.

[30]  Eric J. Simon,et al.  Structural model for the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide , 1995, Nature Structural Biology.

[31]  I. Lieberburg,et al.  Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. , 1990, Science.

[32]  H. Vinters,et al.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Benzinger,et al.  Propagating structure of Alzheimer’s β-amyloid(10–35) is parallel β-sheet with residues in exact register , 1998 .

[34]  J R Ghilardi,et al.  1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. , 1995, Biochemistry.

[35]  J. Meienhofer,et al.  Solid phase synthesis without repetitive acidolysis. Preparation of leucyl-alanyl-glycyl-valine using 9-fluorenylmethyloxycarbonylamino acids. , 2009, International journal of peptide and protein research.

[36]  R. Roos,et al.  Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D) , 1998, Acta Neuropathologica.

[37]  R. Roos,et al.  Hereditary Cerebral Hemorrhage with Amyloidosis‐Dutch type (HCHWA‐D): II ‐ A Review of Histopathological Aspects , 1996, Brain pathology.

[38]  F E Cohen,et al.  Pathologic conformations of prion proteins. , 1998, Annual review of biochemistry.